|Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma|
J Zhao, AX Chen, RD Gartrell, AM Silverman, L Aparicio, T Chu, ...
Nature medicine 25 (3), 462-469, 2019
|Epidermal growth factor receptor–mediated signal transduction in the development and therapy of gliomas|
MK Nicholas, RV Lukas, NF Jafri, L Faoro, R Salgia
Clinical Cancer Research 12 (24), 7261-7270, 2006
|Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges|
AP Mann, E Grebenciucova, RV Lukas
Therapeutics and clinical risk management 10, 517, 2014
|ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.|
DA Reardon, J Schuster, DD Tran, KL Fink, LB Nabors, G Li, DA Bota, ...
Journal of Clinical Oncology 33 (15_suppl), 2009-2009, 2015
|An overview of meningiomas|
RA Buerki, CM Horbinski, T Kruser, PM Horowitz, CD James, RV Lukas
Future Oncology 14 (21), 2161-2177, 2018
|IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma|
E Ladomersky, L Zhai, A Lenzen, KL Lauing, J Qian, DM Scholtens, ...
Clinical cancer research 24 (11), 2559-2573, 2018
|Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges|
MK Nicholas, RV Lukas, S Chmura, B Yamini, M Lesniak, P Pytel
Seminars in oncology 38 (2), 243-253, 2011
|Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial|
EA Chiocca, SY John, RV Lukas, IH Solomon, KL Ligon, H Nakashima, ...
Science translational medicine 11 (505), 2019
|Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study|
SM Gadgeel, RV Lukas, J Goldschmidt, P Conkling, K Park, D Cortinovis, ...
Lung Cancer 128, 105-112, 2019
|Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma|
RV Lukas, J Rodon, K Becker, ET Wong, K Shih, M Touat, M Fassò, ...
Journal of neuro-oncology 140 (2), 317-328, 2018
|Newly diagnosed glioblastoma: a review on clinical management|
RV Lukas, DA Wainwright, E Ladomersky, S Sachdev, AM Sonabend, ...
Oncology (Williston Park, NY) 33 (3), 91, 2019
|Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities|
M Kak, R Nanda, EE Ramsdale, RV Lukas
Journal of Clinical Neuroscience 22 (4), 632-637, 2015
|Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy|
A Daif, RV Lukas, NP Issa, A Javed, S VanHaerents, AT Reder, JX Tao, ...
Epilepsy & Behavior 80, 331-336, 2018
|The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy|
L Zhai, M Dey, KL Lauing, G Gritsina, R Kaur, RV Lukas, MK Nicholas, ...
Journal of Clinical Neuroscience 22 (12), 1964-1968, 2015
|Structure of neuroscience clerkships in medical schools and matching in neuromedicine|
DV Albert, H Yin, C Amidei, KS Dixit, JR Brorson, RV Lukas
Neurology 85 (2), 172-176, 2015
|Update on diagnostic practice: tumors of the nervous system|
P Pytel, RV Lukas
Archives of pathology & laboratory medicine 133 (7), 1062-1077, 2009
|The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma|
E Ladomersky, DM Scholtens, M Kocherginsky, EA Hibler, ET Bartom, ...
Frontiers in pharmacology 10, 200, 2019
|Management of glioblastoma in elderly patients|
JS Young, SJ Chmura, DA Wainwright, B Yamini, KB Peters, RV Lukas
Journal of the neurological sciences 380, 250-255, 2017
|Student assessment by objective structured examination in a neurology clerkship|
RV Lukas, T Adesoye, S Smith, A Blood, JR Brorson
Neurology 79 (7), 681-685, 2012
|State-of-the-art considerations in small cell lung cancer brain metastases|
RV Lukas, V Gondi, DO Kamson, P Kumthekar, R Salgia
Oncotarget 8 (41), 71223, 2017